TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2647051

Group type: EXPERIMENTAL
Intervention: Reconstructive surgery
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Reconstructive surgery with subsequent physical training
Number of subjects: 75

Group type: COMPARATOR
Intervention: Physical training alone
Number of subjects: 75
Study: 31841078

Group type: EXPERIMENTAL
Intervention: Lumbar Stabilization Treatment (LST)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cognitive Functional Treatment (CFT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 31267969

Group type: EXPERIMENTAL
Intervention: Two-view digital breast tomosynthesis
Number of subjects: 182

Group type: COMPARATOR
Intervention: Digital mammography
Number of subjects: 182
Study: 28317885

Group type: EXPERIMENTAL
Intervention: Alginate-based reflux suppressant
Number of subjects: 100

Group type: COMPARATOR
Intervention: Magnesium-aluminium antacid gel
Number of subjects: 100
Study: 25111276

Group type: EXPERIMENTAL
Intervention: Nursing intervention program for outpatient rehabilitation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Nursing intervention program
Number of subjects: 85
Study: 24791346

Group type: EXPERIMENTAL
Intervention: Permethrin 5% lotion applied twice with a one week interval
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single dose of oral ivermectin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Two doses of ivermectin
Number of subjects: 60
Study: 22129125

Group type: EXPERIMENTAL
Intervention: 28-day feeding group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 56-day feeding group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both feeding groups
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (immediate slaughter)
Number of subjects: 31
Study: 19336428

Group type: EXPERIMENTAL
Intervention: Bilateral recession (BR)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Unilateral recession-resection (RR)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study: 16449486

Group type: EXPERIMENTAL
Intervention: Nalmefene 25 mg/day
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Nalmefene 50 mg/day
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Nalmefene 100 mg/day
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 15290730

Group type: EXPERIMENTAL
Intervention: LEF (10 mg/day, no loading dose) + MTX
Number of subjects: 192

Group type: COMPARATOR
Intervention: PLA + MTX switched to LEF (10 mg/day, no loading dose)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: LEF (initially randomized)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: LEF (no loading dose)
Number of subjects: 192
Study: 11273907

Group type: EXPERIMENTAL
Intervention: Insulin-enhanced cardioplegia (Humulin R 10 IU/L, Insulin group, n = 243)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Standard blood cardioplegia (Control group, n = 258)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Insulin-enhanced cardioplegia
Number of subjects: 501

Group type: COMPARATOR
Intervention: Standard blood cardioplegia
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Overall population (n = 501)
Number of subjects: 501
Study: 9032510

Group type: EXPERIMENTAL
Intervention: Awareness of breathing recording
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Breathing through mouthpiece
Number of subjects: 74

Group type: COMPARATOR
Intervention: Misled into believing breathing was not recorded
Number of subjects: 74

Group type: COMPARATOR
Intervention: Breathing recorded for 5 min
Number of subjects: 74
Study: 8286287

Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac (75 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 50
Study: 31433134

Group type: EXPERIMENTAL
Intervention: EndoUltra: 2.5 ml of 7% MA for 30 s, followed by EndoUltra activation for 30 s
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EndoSafe: EndoSafe irrigation system for 1 minute using 5 ml of 7% MA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Side‐vented needle: 30 gauge needle irrigation for 1 min using 5 ml of 7% MA
Number of subjects: 30
Study: 28407232

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (cooling to 33 ± 1 °C core temperature) initiated out of hospital and/or in hospital
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (cooling in hospital only)
Number of subjects: 1812

Group type: COMPARATOR
Intervention: No therapeutic hypothermia (not cooled)
Number of subjects: 1812
Study: 25450818

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day, n=46)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg/day, n=42)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Comparison of Pioglitazone and Metformin
Number of subjects: 88
Study: 23279120

Group type: EXPERIMENTAL
Intervention: Self-management intervention plus usual care
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 82
Study: 21685236

Group type: EXPERIMENTAL
Intervention: Red meat intake
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Serum TIBC
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Serum UIBC
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Serum ferritin, iron, transferrin saturation
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Polymorphisms in genes involved in iron homeostasis
Number of subjects: 356
Study: 18281113

Group type: EXPERIMENTAL
Intervention: Magnesium orotate (6000 mg for 1 month, 3000 mg for about 11 months, n=40)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (n=39)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Magnesium orotate
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 16948809

Group type: EXPERIMENTAL
Intervention: RWJ-351647 (1, 2, and 5 mg doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RWJ-351647 (5 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RWJ-351647
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15280142

Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alveofact
Number of subjects: 0
Study: 11380515

Group type: EXPERIMENTAL
Intervention: Vitamin E therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NG-Monomethyl-L-arginine (L-NMMA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Isotonic exercise, ACh, SNP
Number of subjects: 26
Study: 9421595

Group type: EXPERIMENTAL
Intervention: One-incision technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Two-incision technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 30
Study: 8308937

Group type: EXPERIMENTAL
Intervention: Methadone combined with clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clonidine alone
Number of subjects: 0
Study: 3471304

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 25

Group type: COMPARATOR
Intervention: Indalpine or Citalopram
Number of subjects: 25
Study: 27577039

Group type: EXPERIMENTAL
Intervention: Brief educational and motivational drinking-reduction interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27538352

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24929883

Group type: EXPERIMENTAL
Intervention: Halobetasol 0.05% ointment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 20
Study: 22738918

Group type: EXPERIMENTAL
Intervention: Desmoteplase
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 20634440

Group type: EXPERIMENTAL
Intervention: Sources of Strength suicide prevention program
Number of subjects: 453
Study: 18566839

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Combination of intravenous dexamethasone and oral cyclophosphamide therapy
Number of subjects: 52
Study: 16783294

Group type: COMPARATOR
Intervention: Vaginal suppositories containing Lactobacillus acidofilus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vaginal suppositories containing Lactobacillus acidofilus + oral Lactobacillus paracasei subsp paracasei F19
Number of subjects: 60
Study: 14557449

Group type: EXPERIMENTAL
Intervention: High dose soy isoflavones (1.0 g soy extracts, approximately 80 mg isoflavones)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Mid-dose soy isoflavones (0.5 g starch, 0.5 g soy extracts, approximately 40 mg isoflavones)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo (1 g starch)
Number of subjects: 203
Study: 11099619

Group type: EXPERIMENTAL
Intervention: Neuropsychological functioning (IQ < 70)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Neuropsychological functioning (IQ = 70-89)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Neuropsychological functioning (IQ > 90)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Motor dysfunction (reduced muscle mass)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Cortical atrophy
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Week 48 neuropsychological functioning
Number of subjects: 722
Study: 8871338

Group type: EXPERIMENTAL
Intervention: Self-hypnotic relaxation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no self-hypnotic relaxation)
Number of subjects: 30
Study: 1497048

Group type: EXPERIMENTAL
Intervention: Paced respiration
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Muscle relaxation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Alpha-wave electroencephalographic biofeedback
Number of subjects: 33
Study: 6338794

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline injection (placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (after placebo failure)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intralesional steroid therapy (combined results)
Number of subjects: 20
Study: 30767962

Group type: EXPERIMENTAL
Intervention: Depression in patients with cancer
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Depression in family caregivers (FCs)
Number of subjects: 716
Study: 29153532

Group type: EXPERIMENTAL
Intervention: Blind pushing technique for PICC placement through brachial vein access
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Brachial vein access
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Nonbrachial vein access
Number of subjects: 1043
Study: 27009620

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (n=833)
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (n=821)
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockade (n=830)
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Evening variability independent of the mean (before treatment)
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Morning measurement of BPV
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Home BPV captured after monotherapy
Number of subjects: 2484
Study: 25401780

Group type: EXPERIMENTAL
Intervention: Optional mucosal sampling
Number of subjects: 211

Group type: COMPARATOR
Intervention: Volunteers from Soweto
Number of subjects: 211

Group type: COMPARATOR
Intervention: Volunteers from Klerksdorp
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Volunteers over 25 years of age
Number of subjects: 211
Study: 23045543

Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 319

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 319
Study: 20142543

Group type: EXPERIMENTAL
Intervention: Angiotensin-receptor blocker (losartan potassium) or angiotensin-converting enzyme inhibitor (enalapril maleate)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Daytime ambulatory systolic BP
Number of subjects: 147

Group type: COMPARATOR
Intervention: Daytime ambulatory diastolic BP
Number of subjects: 147

Group type: COMPARATOR
Intervention: Nighttime ambulatory systolic BP
Number of subjects: 147

Group type: COMPARATOR
Intervention: 24-hour ambulatory systolic BP
Number of subjects: 147
Study: 17324145

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily for 12 weeks, followed by placebo for 2 weeks and then metoprolol succinate 95 mg once daily for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol succinate 95 mg for 12 weeks, placebo for 2 weeks and then nebivolol 5 mg for 12 weeks
Number of subjects: 0
Study: 17120843

Group type: EXPERIMENTAL
Intervention: Primary learning with landmark cognitive style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary learning with landmark cognitive style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary learning with route cognitive style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary learning with survey cognitive style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary learning with route cognitive style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary learning with survey cognitive style
Number of subjects: 0
Study: 12066489

Group type: EXPERIMENTAL
Intervention: Southern Implants
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Steri-Oss
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ITI
Number of subjects: 72

Group type: COMPARATOR
Intervention: All implant systems
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ITI and Steri-Oss
Number of subjects: 72
Study: 10703876

Group type: EXPERIMENTAL
Intervention: Weight loss with exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weight loss without exercise training (diet-only group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss (both groups)
Number of subjects: 0
Study: 8724090

Group type: EXPERIMENTAL
Intervention: Lumbar disc surgery for patients with disc herniation only
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Lumbar disc surgery for patients with diagnoses other than disc herniation
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Predictor score for patients with disc herniation only
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Pain management approach for high-risk patients
Number of subjects: 164
Study: 1718158

Group type: EXPERIMENTAL
Intervention: Active treatment (encainide/flecainide)
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: Accelerated idioventricular rhythm < 100 beats/min
Number of subjects: 1498
Study: 6224684

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cotrimoxazole 160/800 mg twice daily
Number of subjects: 40
Study: 31699046

Group type: EXPERIMENTAL
Intervention: Embedding Package (intervention to increase uptake of structured self-management education)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Embedding Package
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 66
Study: 29180206

Group type: EXPERIMENTAL
Intervention: Ropivacaine wound infiltration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo wound infiltration
Number of subjects: 40
Study: 25101527

Group type: EXPERIMENTAL
Intervention: Feedback (FB) using the OQ‐Analyst and Outcome Questionnaire‐45.2
Number of subjects: 259

Group type: COMPARATOR
Intervention: No Feedback (NFB)
Number of subjects: 259
Study: 24832559

Group type: EXPERIMENTAL
Intervention: Film-coated ethionamide tablets (250 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sugar-coated ethionamide tablets (250 mg)
Number of subjects: 40
Study: 23190833

Group type: EXPERIMENTAL
Intervention: Leukocyte- and platelet-rich fibrin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Vaselitulle (petroleum jelly mesh)
Number of subjects: 68
Study: 19052457

Group type: EXPERIMENTAL
Intervention: Good Behavior Game intervention (n = 263)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Control condition (n = 214)
Number of subjects: 477
Study: 17894303

Group type: EXPERIMENTAL
Intervention: Weight-based ribavirin (RBV) 800-1400 mg/day
Number of subjects: 5027

Group type: COMPARATOR
Intervention: Flat-dose ribavirin (RBV) 800 mg/day
Number of subjects: 5027

Group type: EXPERIMENTAL
Intervention: Weight-based RBV in genotype 1 patients
Number of subjects: 5027

Group type: COMPARATOR
Intervention: Flat-dose RBV in genotype 1 patients
Number of subjects: 5027

Group type: EXPERIMENTAL
Intervention: Weight-based RBV in genotype 1 patients with high baseline viral load
Number of subjects: 5027

Group type: COMPARATOR
Intervention: Flat-dose RBV in genotype 1 patients with high baseline viral load
Number of subjects: 5027

Group type: EXPERIMENTAL
Intervention: Weight-based RBV in genotype 2/3 patients
Number of subjects: 5027

Group type: COMPARATOR
Intervention: Flat-dose RBV in genotype 2/3 patients
Number of subjects: 5027
Study: 14766435

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11385386

Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (36 degrees C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (30 degrees C)
Number of subjects: 24
Study: 9227164

Group type: EXPERIMENTAL
Intervention: etidronate + sodium fluoride (NaF) 25 mg twice daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: etidronate + placebo
Number of subjects: 47
Study: 7958497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low dose ANG II infusion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High dose ANG II infusion
Number of subjects: 11
Study: 3516085

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 30977767

Group type: EXPERIMENTAL
Intervention: Higher serum sodium levels (≥141 mmol/L)
Number of subjects: 8813

Group type: EXPERIMENTAL
Intervention: Higher baseline serum sodium levels
Number of subjects: 8813
Study: 29033294

Group type: EXPERIMENTAL
Intervention: Acetaminophen 4,000 mg/day
Number of subjects: 547

Group type: COMPARATOR
Intervention: Diclofenac 150 mg/day
Number of subjects: 547

Group type: COMPARATOR
Intervention: Acetaminophen 4,000 mg/day + Diclofenac 150 mg/day
Number of subjects: 547
Study: 27737649

Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (2 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Benzodiazepine tapering
Number of subjects: 48
Study: 24134409

Group type: EXPERIMENTAL
Intervention: WHO growth standards
Number of subjects: 78

Group type: COMPARATOR
Intervention: NCHS growth references
Number of subjects: 78
Study: 23945723

Group type: EXPERIMENTAL
Intervention: PE-formula
Number of subjects: 18

Group type: COMPARATOR
Intervention: S-formula
Number of subjects: 18
Study: 20462568

Group type: EXPERIMENTAL
Intervention: CP+VF+CR
Number of subjects: 68

Group type: COMPARATOR
Intervention: EXP
Number of subjects: 68

Group type: COMPARATOR
Intervention: CP+VF
Number of subjects: 68
Study: 18249478

Group type: EXPERIMENTAL
Intervention: IFN-alpha as an adjuvant of HBV vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFN-alpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (HBV vaccine without IFN-alpha)
Number of subjects: 0
Study: 16754246

Group type: EXPERIMENTAL
Intervention: Semantic word lists (e.g., bed, rest, wake)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Phonological word lists (e.g., pole, bowl, hole)
Number of subjects: 3
Study: 12796026

Group type: COMPARATOR
Intervention: CHOP-21
Number of subjects: 959

Group type: COMPARATOR
Intervention: CHOP-14
Number of subjects: 959

Group type: COMPARATOR
Intervention: CHOEP-21
Number of subjects: 959

Group type: COMPARATOR
Intervention: CHOEP-14
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: CHOP-14 with rhG-CSF
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: CHOEP-21 and CHOEP-14
Number of subjects: 959
Study: 10926073

Group type: COMPARATOR
Intervention: Sham block (Group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peritonsillar block with bupivacaine 0.25% before tonsillectomy (Group II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peritonsillar block with bupivacaine 0.25% immediately after surgery (Group III)
Number of subjects: 30
Study: 8929202

Group type: EXPERIMENTAL
Intervention: Water Immersion (WI)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Head-Down Tilt (HDT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ambulatory Control (AC)
Number of subjects: 7
Study: 1430354

Group type: EXPERIMENTAL
Intervention: Stokogard
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hollister Moisture Barrier
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydropel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ivy Shield
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Shield Skin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dermofilm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Uniderm
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated area)
Number of subjects: 20
Study: 6941637

Group type: EXPERIMENTAL
Intervention: Exposure to a cold room (‐10 degrees C) and inhalation of very cold air (‐35 degrees C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure to 10 and 0 degrees C environmental temperature and inhalation of moderately cold air (‐10 degrees C)
Number of subjects: 0
Study: 31178009

Group type: EXPERIMENTAL
Intervention: Developing Relationships that Include Values of Eating and Exercise (DRIVE) intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 16
Study: 28032303

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HCT) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0